From WikiProjectMed
Jump to navigation Jump to search
Monoclonal antibody
TypeFab fragment
SourceHumanized (from mouse)
Trade namesPraxbind
Other namesBI-655075
Clinical data
Main usesReversal of dabigatran[1]
Side effectsHeadache, nausea, constipation[1]
  • AU: B2
Routes of
Typical dose5 gram[1]
External links
License data
Legal status
Chemical and physical data
Molar mass47782.71 g·mol−1

Idarucizumab, sold under the brand name Praxbind, is a medication used to reverse the effects of dabigatran.[1] Specifically it is used if severe bleeding or urgent surgery is required.[1] It is given by injection into a vein.[3]

Common side effects include headache, nausea, and constipation.[1] Severe side effects may include blood clots and allergic reactions.[1] It is a monoclonal antibody that works by binding to and inactivating dabigatran.[1][2]

Idarucizumab was approved for medical use in the United States and Europe in 2015.[1][2] In the United Kingdom it costs the NHS about £2,400 for a dose as of 2021.[3] This amount in the United States costs about 4,500 USD.[4]

Medical uses

Dabigatran can be started again once 24 hours has passed from this medication being given.[3]


It is given as a dose of 5 gram.[1] Occasionally a second 5 gram dose may be used.[3]

Society and culture


Idarucizumab is the International nonproprietary name (INN).[5] The description was updated in 2016.[6] Idarucizumab is the United States Adopted Name (USAN).[7]

See also


  1. 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 "Praxbind- idarucizumab injection". DailyMed. 1 December 2019. Archived from the original on 25 March 2021. Retrieved 19 August 2020.
  2. 2.0 2.1 2.2 "Praxbind EPAR". European Medicines Agency (EMA). Archived from the original on 25 October 2020. Retrieved 16 October 2020.
  3. 3.0 3.1 3.2 3.3 BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 131. ISBN 978-0857114105.
  4. "Praxbind Prices, Coupons & Patient Assistance Programs". Archived from the original on 2 May 2021. Retrieved 25 November 2021.
  5. World Health Organization (2014). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 71". WHO Drug Information. 28 (1): 90–91. hdl:10665/331151.
  6. World Health Organization (2016). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 76". WHO Drug Information. 30 (3): 544. hdl:10665/331020.
  7. Statement On A Nonproprietary Name Adopted By The USAN Council - Idarucizumab Archived 2015-06-27 at the Wayback Machine, American Medical Association.

External links

External sites: